In this exciting video, Dr. Viral Desai interviews HFpEF expert Dr. Barry Borlaug to discuss the CAMEO-DAPA clinical trial and its implications for heart failure with preserved ejection fraction (HFpEF) patients. Dr. Borlaug provides his expert insights into the trial's findings, which examined the effects of dapagliflozin on invasive hemodynamics in HFpEF patients. Dr. Borlaug and Dr. Desai discuss the potential benefits and risks of dapagliflozin in HFpEF patients, as well as its potential impact on future HFpEF treatment and management strategies. This video is a valuable resource for healthcare professionals and patients alike, providing the latest insights from two leading experts in the field of HFpEF. Don't miss out on this engaging and informative discussion with Dr. Viral Desai and Dr. Barry Borlaug!

свернуть